Island Pharmaceuticals (ASX:ILA) formalised a three-year cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases and The Geneva Foundation.
The strategic collaboration aims to accelerate the development of Galidesivir, a promising antiviral candidate targeting the deadly Marburg Virus Disease.
Following the announcement, Island’s shares rose by 14.86%, reflecting strong investor confidence in the company’s regulatory trajectory.
The partnership focuses on progressing Galidesivir via the FDA Animal Rule pathway, a specialised regulatory track used when human efficacy trials are unethical or unfeasible.
Under the CRADA, the parties will design and execute critical non-human primate studies, which serve as the primary evidence for a future New Drug Application.